AstraZeneca Forxiga recommended for nod in EU for chronic heart failure Ruchika Sharma20 Dec 2022 5:30 PM ISTHeart failue is a life-threatening chronic disease in which the heart cannot pump enough blood around the body, affecting 15 million people in the EU.
Setback to AstraZeneca: Imfinzi fails as monotherapy for non-small lung cancer Ruchika Sharma20 Dec 2022 1:30 PM ISTImfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80...
Experts say patient selection for AstraZeneca, Daiichi breast cancer drug needs improvement Ruchika Sharma10 Dec 2022 1:30 PM ISTUK: The rush to use AstraZeneca and Daiichi-Sankyo's drug Enhertu to treat certain types of breast cancer has far outpaced doctors' ability to...
AstraZeneca to sell West Chester site to National Resilience Ruchika Sharma4 Dec 2022 11:00 AM ISTAstraZeneca expects to complete the sale in the first quarter of 2023, with a phased transition of services.
AstraZeneca to buy Neogene Therapeutics for over Rs 2605 crore Ruchika Sharma3 Dec 2022 12:15 PM ISTNeogene will operate as a wholly owned subsidiary of AstraZeneca, with operations in Amsterdam, the Netherlands and California, US.
AstraZeneca enters into USD 402 million global licensing agreement with C4X Discovery Holdings Ruchika Sharma29 Nov 2022 11:00 AM ISTNRF2 is an important natural regulator, controlling the expression of antioxidant genes, and it plays a key role in cellular defense against external...
AstraZeneca Imfinzi plus chemotherapy recommended for marketing authorisation in EU for advanced biliary tract cancer Ruchika Sharma15 Nov 2022 5:44 PM ISTUK: AstraZeneca's Imfinzi (durvalumab) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line treatment of adult...
AstraZeneca- Daiichi Sankyo Enhertu recommended for nod in EU by CHMP for patients with previously treated HER2-positive advanced gastric cancer Ruchika Sharma15 Nov 2022 12:15 PM ISTEnhertu is a HER2-directed ADC.
AstraZeneca tops quarterly estimates buoyed by cancer drug sales Ruchika Sharma13 Nov 2022 10:00 AM ISTDelaware: AstraZeneca on Thursday topped analysts' expectations for third-quarter profit and revenue, helped by sales of its key cancer drugs, and...
AstraZeneca gets USFDA nod for Imfinzi, Imjudo with chemotherapy to treat metastatic non-small cell lung cancer Ruchika Sharma11 Nov 2022 2:30 PM ISTImfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80...
AstraZeneca PT027 recommended by FDA advisory committee as new rescue treatment for asthma Ruchika Sharma9 Nov 2022 1:30 PM ISTAsthma is a chronic, inflammatory, variable respiratory disease that affects as many as 339 million people worldwide, including over 25 million in the...
AstraZeneca Asthma drug Fasenra fails one main goal in study of chronic immune disease Ruchika Sharma28 Oct 2022 1:30 PM ISTUK: High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary...
